Vanguard Capital Management
ENSC icon

Vanguard Capital Management’s Ensysce Biosciences ENSC Stock Holding History

Vanguard Capital Management’s Portfolio ENSC Stock Details ENSC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.73K Hold
12,854
– – ﹤0.01% 4072
2026
Q1 		$6.93K Buy
+12,854
New +$8.15K ﹤0.01% 4029

Other funds holding ENSC

Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
TIAM2
Tru Independence Asset Management 2 Portland, Oregon $185M AUM 20.3% 1-Year Est. Return

Vanguard Capital Management's ENSC Position: Q2 2026 in Review

Vanguard Capital Management held its Ensysce Biosciences (ENSC) position steady in Q2 2026 at 12,854 shares worth $3.73K. The position accounts for ﹤0.01% of the portfolio, ranked #4072.

Vanguard Capital Management first reported a position in ENSC in Q1 2026 and has held it in 2 quarters since. The position peaked at $6.93K in Q1 2026. 18 funds tracked by Wall St. Rank hold ENSC as of Q2 2026.

  • Vanguard Capital Management held 12,854 shares of Ensysce Biosciences worth $3.73K as of Q2 2026.
  • Vanguard Capital Management left its Ensysce Biosciences share count unchanged in Q2 2026.
  • Ensysce Biosciences made up ﹤0.01% of Vanguard Capital Management's portfolio in Q2 2026, its #4072 holding.
  • Vanguard Capital Management first reported a position in Ensysce Biosciences in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Capital Management's Ensysce Biosciences position peaked at $6.93K in Q1 2026.
  • 18 funds tracked by Wall St. Rank held Ensysce Biosciences as of Q2 2026.

Based on Vanguard Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.